Bone Mineral Density
Routine vitamin D and calcium supplementation in older adults is not supported for lowering the incidence of osteoporosis-related fractures.
Tocilizumab treatment for 2 years was shown to reduce levels of bone loss in patients with ACPA-positive RA.
Growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
The UK National Osteoporosis Guideline Group released updated guidelines for the prevention of fragility fracture in postmenopausal women and in men aged 50 years or older.
Total hip BMD was associated with heart failure risk in black and non-black men, with an interaction by race.
Researchers compared the efficacy of dual-energy x-ray absorptiometry with lateral x-ray in assessing vertebral fractures.
This week, a phase III trial for investigational drug voclosporin for lupus nephritis treatment was approved, prolonged insomnia may lead to less robust bone formation — causing osteoporosis and bone fractures — and researchers found that women who drink a moderate amount of alcohol daily have a reduced risk of developing systemic lupus erythmatosus.
Three-year fracture study examines the effects of osteoporosis drug denosumab on fractures, bone mineral density, and bone turnover markers in postmenopausal women with osteoporosis.
Prospective observational cohort study examines association between post-ICU administration of anti-fracture therapy or glucocorticoids and longitudinal changes in bone mineral density.
Testosterone treatments help improve volumetric bone mineral density and bone strength in elderly men with low testosterone.
The trabecular bone score may provides an acute, albeit indirect, measurement of bone quality in patients with type 2 diabetes.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
Long-term tenofovir treatment for hepatitis B infection is linked with abnormal phosphorus metabolism in a recent study.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Higher Trabecular Bone Scores were found in postmenopausal women taking hormone replacement therapy compared with women who had never used hormone therapy.
DMARDs have been shown to be effective in halting progressive bone loss in rheumatoid arthritis.
Pediatric and adolescent patients who used stimulants to treat ADHD were found to have low bone density and bone mineral content.
Kenneth Saag, MD, president of the National Osteoporosis Foundation (NOF), co-chair of the National Bone Health Alliance, and Rheumatology Advisor advisory board member, reports on the recent changes that have led to the current state of osteoporosis treatment in the US.
Findings showing that sedentary time was not significantly linked to bone mineral density weaken the previous association between physical activity and bone mineral density.
The use of ARBs was associated with lower incidence of non-vertebral fractures than ACE inhibitors or CCBs.
Denosumab treatment led to significant increases in BMD at the lumbar spine and total hip at 12 months as compared to risedronate, both in patients receiving continuing glucocorticoid therapy and those just starting glucocorticoid therapy.
To better predict bone loss during the menopausal transition, researchers created the bone balance index using bone turnover markers to measure net bone formation.
Interval changes in bone mineral density (BMD) detected by dual-energy x-ray absorptiometry (DXA) are associated with fracture risk in women starting osteoporosis treatment
In women with premature ovarian failure, hormone replacement therapy was associated with greater increases in bone mineral density.
Lower BMD and abnormal trabecular bone microstructure with reduced bone strength was found in men with early HIV infection
After introducing the electronic health record pop-up messages, the rate of DXA prescriptions increased.
Advanced glycation endproducts were linked to reduced bone material properties in postmenopausal women with type 2 diabetes.
High doses of folic acid appeared to mitigate the effects of bone loss.
Amgen and UCB announced results from a phase 3 study evaluating romosozumab for the treatment of osteoporosis in men.
The usage of bisphosphonates decreased as a result of safety announcements issued by the United States Food and Drug Administration (FDA) regarding potential adverse effects of bisphosphonates after hip fracture.
Rheumatology Advisor Articles
- Raynaud Phenomenon, Migraine Linked to aPS/PT Antibodies in Primary Antiphospholipid Syndrome
- Case Study: A Syncopal Episode During a Camping Trip
- Then and Now: The Crisis of Physician Suicides
- Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA
- Aspirin Similar to Rivaroxaban for VTE Prophylaxis After Hip, Knee Arthroplasty
- FDA Advises Recall: Limbrel May Be Linked to Drug-Induced Liver Injury
- Allopurinol Use May Lower Risk for Peripheral Arterial Disease
- Managing Treatment Nonadherence in Rheumatic Diseases
- Optimal Fibromyalgia Management Includes Individualized, Multimodal Therapy
- Risk for COPD, Asthma Among Women With Rheumatoid Arthritis: Nurses' Health Study
- Ocular Complications of Gout: The Spectrum of Urate Crystal Deposition
- Digital Medicine Innovations Expand Access to Rural, Low-Income Communities
- Elevated Serum Uric Acid Levels May Increase Risk for Dementia in Older Adults
- Implications of the Regulatory Accountability Act on Public Health
- Synovial Joint Biopsy Techniques: Arthroscopy vs Ultrasound-Guided Methods